Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2002Arthritis & Rheumatism

Long‐term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin‐1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double‐blind, placebo‐controlled trial

View Full Paper
Ask AI
Bookmark
Share

Authors

GNGeorge NukiWestern General HospitalBBBarry BresnihanUniversity College DublinMBMoraye B. BearUniversity of Connecticut

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Nuki et al. (2002) studied this question.

synapsesocial.com/papers/6a0f4a89b997c1a6759bcdcchttps://doi.org/10.1002/art.10578
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritis1995 · 901 citations
  2. 2The Role of the Interleukin-1–Receptor Antagonist in Blocking Inflammation Mediated by Interleukin-12000 · 382 citations
  3. 3A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis2000 · 1,749 citations
  4. 4TNFα—A PIVOTAL ROLE IN RHEUMATOID ARTHRITIS?1992 · 388 citations
  5. 5Biologic basis for interleukin-1 in disease1996 · 4,381 citations